Secretome
  • Home
  • Pipeline
  • Our Science
  • Leadership
  • News and Publications
    • News
    • Publications
Select Page

Sharma 2017 Commentary

by secretome | Oct 3, 2022

Recent Posts

  • NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure
  • NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office
  • Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting
  • Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors
  • Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury
  • Facebook
  • Twitter
  • Instagram
© 2022 Secretome | Reinecke-Design.com